Leonid Timashev
Stock Analyst at RBC Capital
(1.95)
# 2,960
Out of 4,732 analysts
61
Total ratings
35.09%
Success rate
-5.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Outperform | $18 | $3.49 | +415.76% | 4 | Jan 15, 2025 | |
| PYXS Pyxis Oncology | Reiterates: Outperform | $10 → $8 | $1.50 | +433.33% | 5 | Dec 20, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $80 → $82 | $45.74 | +79.27% | 2 | Dec 18, 2024 | |
| LEGN Legend Biotech | Reiterates: Outperform | $86 | $32.66 | +163.32% | 12 | Dec 9, 2024 | |
| BHVN Biohaven | Reiterates: Outperform | $58 → $61 | $37.59 | +62.28% | 9 | Dec 4, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $130 → $131 | $91.94 | +42.49% | 7 | Oct 4, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $32 → $42 | $26.26 | +59.94% | 9 | Sep 20, 2024 | |
| NAMS NewAmsterdam Pharma Company | Reiterates: Outperform | $31 | $23.55 | +31.63% | 5 | Sep 5, 2024 | |
| DSGN Design Therapeutics | Reiterates: Sector Perform | $4 | $5.06 | -20.95% | 8 | Aug 6, 2024 |
COMPASS Pathways
Jan 15, 2025
Reiterates: Outperform
Price Target: $18
Current: $3.49
Upside: +415.76%
Pyxis Oncology
Dec 20, 2024
Reiterates: Outperform
Price Target: $10 → $8
Current: $1.50
Upside: +433.33%
Cytokinetics
Dec 18, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $45.74
Upside: +79.27%
Legend Biotech
Dec 9, 2024
Reiterates: Outperform
Price Target: $86
Current: $32.66
Upside: +163.32%
Biohaven
Dec 4, 2024
Reiterates: Outperform
Price Target: $58 → $61
Current: $37.59
Upside: +62.28%
Axsome Therapeutics
Oct 4, 2024
Maintains: Outperform
Price Target: $130 → $131
Current: $91.94
Upside: +42.49%
Edgewise Therapeutics
Sep 20, 2024
Maintains: Outperform
Price Target: $32 → $42
Current: $26.26
Upside: +59.94%
NewAmsterdam Pharma Company
Sep 5, 2024
Reiterates: Outperform
Price Target: $31
Current: $23.55
Upside: +31.63%
Design Therapeutics
Aug 6, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $5.06
Upside: -20.95%